Gilead Sciences, Inc. (OQ:GILD)
Business Focus: Pharmaceuticals
Apr 18, 2024 01:45 pm ET
Gilead Sciences Publishes 2023 ESG Impact Report
NORTHAMPTON, MA / ACCESSWIRE / April 18, 2024 / Gilead Sciences published its 2023 Environmental, Social and Governance (ESG) Impact Report, which uses the ESG framework to highlight the successes and achievements of the prior year.
Apr 08, 2024 04:05 pm ET
Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2024 financial results and guidance will be released on Thursday, April 25, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s first quarter 2024 financial results and provide a business update.
Apr 02, 2024 09:15 am ET
Gilead Sciences Champions Equal Pay
NORTHAMPTON, MA / ACCESSWIRE / April 2, 2024 / Women represent more than half of Gilead's workforce, and our weighted salary ratio for women to men globally in 2023 was 99.93:100. We'll continue our efforts to champion an environment of equality and inclusion for all.
Mar 28, 2024 08:30 am ET
FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Vemlidy® (tenofovir alafenamide) 25 mg tablets as a once-daily treatment for chronic hepatitis B virus (HBV) infection in pediatric patients six years of age and older and weighing at least 25 kg with compensated liver disease.
Mar 28, 2024 07:00 am ET
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
Gilead Sciences, Inc. (Nasdaq: GILD) and Xilio Therapeutics, Inc. (Nasdaq: XLO) today announced an exclusive license agreement to develop and commercialize Xilio’s Phase 1 tumor-activated IL-12 program, XTX301. Xilio Therapeutics is a...
Mar 28, 2024 07:00 am ET
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
Gilead Sciences, Inc. (Nasdaq: GILD) and Xilio Therapeutics, Inc. (Nasdaq: XLO) today announced an exclusive license agreement to develop and commercialize Xilio’s Phase 1 tumor-activated IL-12 program, XTX301.
Mar 26, 2024 09:15 am ET
Winn Awards Help Physicians Solve Healthcare Disparities
NORTHAMPTON, MA / ACCESSWIRE / March 26, 2024 / Dr. Thomas Odeny grew up in rural Kenya during the height of the HIV epidemic in sub-Saharan Africa. After graduating from medical school at the University of Nairobi, he decided to begin his career in HIV care as a way to give back to his community.
Mar 22, 2024 09:18 am ET
Gilead Sciences Announces Completion of Acquisition of CymaBay
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for approximately $4.3 billion in total equity value. The addition of CymaBay’s investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis (PBC) including pruritus, complements Gilead’s existing liver portfolio and aligns with its long-standing commitment to bringing transformational medicines to patients.
Mar 19, 2024 09:05 am ET
Gilead Helps Launch Türkiye’s First HIV Testing Week
NORTHAMPTON, MA / ACCESSWIRE / March 19, 2024 / Gilead Sciences:
Mar 18, 2024 07:29 pm ET
Center for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink Grant
The Center for Disease Analysis Foundation (CDA Foundation) is thrilled to announce the first-round recipients of the CDAF-Relink grant to connect Hepatitis B and C infected individuals in the United States back to care. The program is funded by an eight-million-dollar grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant program. In this first round, CDA Foundation distributed a total of 2.1 million dollars to the following 14 grantees:
Mar 12, 2024 08:45 am ET
Gilead Science Supports Increasing Diversity in Clinical Trials: 2024 Toward Health Equity Oncology Grant Supports 36 Global Organizations
NORTHAMPTON, MA / ACCESSWIRE / March 12, 2024 / We're committed to increasing diverse representation in clinical trials, especially for those who have been historically underrepresented.
Mar 11, 2024 08:24 am ET
Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Gilead’s cash tender offer for CymaBay Therapeutics, Inc. expired at 11:59 p.m. on March 8, 2024.
Mar 07, 2024 08:15 am ET
Gilead Sciences Aids in Reducing Cancer Care Disparities: Dale Shares Her Breast Cancer Journey and the Power of Information Sharing
NORTHAMPTON, MA / ACCESSWIRE / March 7, 2024 / Gilead Sciences
Mar 06, 2024 04:30 pm ET
Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities
Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from three studies evaluating the efficacy and safety profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) for a broad range of people with HIV, including those with HIV/hepatitis B (HBV) coinfection and HIV/tuberculosis (TB) coinfection. These data and other studies supporting the important role of Biktarvy in the HIV treatment landscape were presented at the 31st Conference on Retroviruses and Opportunistic Infections (
Mar 06, 2024 10:25 am ET
Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 2 clinical study evaluating the investigational combination of islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class capsid inhibitor. These late-breaking data were presented during an oral session at the 31st Conference on Retroviruses and Opportunistic Infections (
Mar 06, 2024 08:00 am ET
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
Gilead Sciences, Inc. (Nasdaq:GILD) and Merus N.V. (Nasdaq:MRUS) today announced a research collaboration, option and license agreement to discover novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. Gilead and Merus agreed to collaborate on the use of Merus’ proprietary Triclonics® platform along with Gilead’s oncology expertise to research and develop multiple, separate preclinical research programs.
Mar 05, 2024 04:35 pm ET
New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19
Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from three real-world retrospective studies being presented at the 31st Conference on Retroviruses and Opportunistic Infections (CROI).
Mar 05, 2024 04:30 pm ET
Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of key data highlighting the breadth of its innovative HIV treatment research pipeline. The latest results explore clinical outcomes from a study evaluating an investigational combination regimen of bictegravir and lenacapavir, new findings from a study evaluating the investigational combination of lenacapavir with broadly neutralizing antibodies (bNAbs), and new proof-of-concept data on GS-1720, a novel once-weekly integrase strand transfer inhibitor (INSTI). The data presented at the 31st Conference on Retroviruses and Opp
Mar 05, 2024 08:45 am ET
Gilead Sciences CEO on Company's Evolution and Commitment to the Bay Area
NORTHAMPTON, MA / ACCESSWIRE / March 5, 2024 / Gilead SciencesOriginally published by SAN FRANCISCO BUSINESS TIMES on bizjournals.com
Feb 29, 2024 12:25 pm ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Everi Holdings Inc. (NYSE – EVRI), Sterling Check Corp. (Nasdaq – S
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Feb 29, 2024 08:30 am ET
Gilead Sciences: National Black HIV/AIDS Awareness Day
NORTHAMPTON, MA / ACCESSWIRE / February 29, 2024 / This year's theme for National Black HIV/AIDS Awareness Day is "Engage, Educate, Empower: Uniting to End HIV/AIDS in Black Communities." We spoke with C. Virginia Fields, President and CEO of National Black Leadership Commission on Health (Black Health), a Gilead grantee, about how together, we can take action toward meaningful change.
Feb 28, 2024 05:15 pm ET
Gilead Announces Funding Initiative To Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.
- 19 Organizations Will Receive a Total of $12.6 Million in Grant Funding Through Gilead's Setting the P.A.C.E. Initiative -
Feb 27, 2024 10:00 am ET
Gilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is providing a total of $12.6 million in grant funding to 19 organizations working to improve the HIV landscape for Black women and girls in the United States. These grants are a part of Gilead’s new Setting the P.A.C.E. (Prevention, Arts and Advocacy, Community, Education) initiative, a three-year commitment toward increasing HIV prevention, anti-stigma and health equity efforts for Black cisgender and Transgender women and girls, who are disproportionately impacted by the HIV epidemic.
Feb 26, 2024 04:05 pm ET
U.S. FDA Approves Expanded Indication for Gilead’s Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) approved a new, expanded indication for Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat people with HIV (PWH) who have suppressed viral loads with known or suspected M184V/I resistance, a common form of treatment resistance. HIV treatment resistance is permanent and irreversible, which can jeopardize future treatment options for PWH. The M184V/I resistance mutation has been found to be present in a range (22-63%) of PWH with pre-ex
Feb 26, 2024 08:30 am ET
Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new clinical data and real-world evidence (RWE) from its antiviral research and development programs at the 31st Conference on Retroviruses and Opportunistic Infections (CROI 2024) taking place from March 3-6. The data from nearly eighty studies across HIV, COVID-19 and
Feb 26, 2024 08:15 am ET
Gilead Sciences and Black HIV/AIDS Awareness Day: Taking Action Toward Meaningful Change
NORTHAMPTON, MA / ACCESSWIRE / February 26, 2024 / This year's theme for National Black HIV/AIDS Awareness Day is "Engage, Educate, Empower: Uniting to End HIV/AIDS in Black Communities." We spoke with C. Virginia Fields, President and CEO of National Black Leadership Commission on Health (Black Health), a Gilead grantee, about how together, we can take action toward meaningful change.
Feb 20, 2024 04:05 pm ET
Gilead Sciences to Present at Upcoming Investor Conferences
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:
Feb 20, 2024 09:25 am ET
Gilead Named One of America’s Most JUST Companies by JUST Capital and CNBC
Company Also Ranked in Top 5 of Pharmaceuticals and Biotech Industry
Feb 13, 2024 08:30 am ET
Gilead Sets Sights on Hepatitis C Elimination As It Marks 10 Years of Curative Therapies
NORTHAMPTON, MA / ACCESSWIRE / February 13, 2024 / Long-time liver specialist Carrie Frenette says she won't ever forget the people she treated for hepatitis C (HCV) before 2013 - the year that the Food and Drug Administration (FDA) approved a Gilead medicine. The medicine was the first curative therapy for HCV.
Feb 12, 2024 11:17 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Masonite International Corporation (NYSE – DOOR), ZeroFox Holdings,
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Feb 12, 2024 08:30 am ET
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
Gilead Sciences, Inc. (Nasdaq: GILD) and CymaBay Therapeutics, Inc. (Nasdaq: CBAY) announced today a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay’s investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis (PBC) including pruritus, complements Gilead’s existing liver portfolio and aligns with its long-standing commitment to bringing transformational medicines to patients.
Feb 09, 2024 11:00 am ET
Gilead Named One of America’s Most JUST Companies by JUST Capital and CNBC
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company has been named one of America’s Most JUST Companies. The ranking, presented by JUST Capital and CNBC, reflects Gilead’s longstanding commitment to operate responsibly by prioritizing stakeholder engagement – including with the patients and communities the company serves, employees and shareholders – while working to create a healthier world for all people. Gilead was recognized on the top 100 list and ranked fifth in the Pharmaceuticals and Biotech industry.
Feb 06, 2024 04:05 pm ET
Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2024 Dividend
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 2.7% in the company’s quarterly cash dividend, beginning in the first quarter of 2024. The increase will result in a quarterly dividend of $0.77 per share of common stock. The dividend is payable on March 28, 2024, to stockholders of record at the close of business on March 15, 2024. Future dividends will be subject to Board approval.
Feb 06, 2024 04:02 pm ET
Gilead Sciences Announces Fourth Quarter and Full Year 2023 Financial Results
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2023.
Feb 06, 2024 08:15 am ET
Gilead Named One of Newsweek America’s Greatest Workplaces for Diversity
NORTHAMPTON, MA / ACCESSWIRE / February 6, 2024 / We believe that innovation thrives when bright, diverse and imaginative minds come together. We're proud to offer an inclusive culture that enables all people to do their best work, and we're happy to be named one of Newsweek America's Greatest Workplaces for Diversity for our efforts.
Feb 01, 2024 04:31 pm ET
Ted Love, MD, Joins Gilead Sciences’ Board of Directors
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Ted Love, MD, has been appointed to the company’s Board of Directors.
Jan 30, 2024 08:30 am ET
Kite Receives U.S. FDA Approval of Manufacturing Process Change Resulting in Reduced Median Turnaround Time for Yescarta® CAR T-cell Therapy
Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has approved a manufacturing process change resulting in a shorter manufacturing time for Yescarta® (axicabtagene ciloleucel). With this approval, Kite’s median turnaround time (TAT) in the U.S. is anticipated to be reduced from 16 days to 14 days.
Jan 30, 2024 08:10 am ET
From the Margins: Gilead’s Book Uniquely Captures What It’s Like To Be Marginalized by Disease
NORTHAMPTON, MA / ACCESSWIRE / January 30, 2024 / Gilead Sciences - The personal journeys of six people in the United Kingdom living with HIV, hepatitis C and cancer - and the challenges they face due to stigma and health inequities - come together in the form of a new, intentionally difficult-to-read book from Gilead. Entitled "From the Margins," each person's experience is deliberately written around the margins of the book in order to raise awareness of what it feels like to live on the periphery of society with a chronic or life-threatening disease.
Jan 29, 2024 05:00 pm ET
Gilead and Arcus Announce Amended Collaboration and Equity Investment
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced an amendment to their collaboration agreement and a separate equity investment by Gilead of $320 million in Arcus common stock at $21.00 per share. The equity investment and collaboration amendment enable accelerated growth of the companies’ joint development programs that span multiple indications. Additionally, Johanna Mercier, Chief Commercial Officer at Gilead Sciences, will join the Arcus Board, bringing Gilead’s total director designees to three. The amendment also includes governance enhancemen
Jan 29, 2024 05:00 pm ET
Gilead and Arcus Announce Amended Collaboration and Equity Investment
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced an amendment to their collaboration agreement and a separate equity investment by Gilead of $320 million in Arcus common stock at $21.00 per share. The equity investment and collaboration amendment enable accelerated growth of the companies’ joint development programs that span multiple indications. Additionally, Johanna Mercier, Chief Commercial Officer at Gilead Sciences, will join the Arcus Board, bringing Gilead’s total director designees to three. The amendment also includes governance enhancemen
Jan 23, 2024 04:05 pm ET
Gilead Sciences to Release Fourth Quarter & Full Year 2023 Financial Results on Tuesday, February 6, 2024
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2023 financial results and guidance will be released on Tuesday, February 6, 2024 after the market closes. At 5:00 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s fourth quarter and full year 2023 financial results and provide a business update.
Jan 23, 2024 09:45 am ET
Gilead Sciences: Art Captures the Experiences of Women Living With Metastatic Breast Cancer
NORTHAMPTON, MA / ACCESSWIRE / January 23, 2024 / For the past 30 years, Pilar Fernandez has navigated living with metastatic breast cancer. And while she's faced a series of related health challenges, it hasn't slowed her down.
Jan 22, 2024 08:30 am ET
Gilead Provides Update on Phase 3 EVOKE-01 Study
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC). EVOKE-01 is evaluating Trodelvy® (sacituzumab govitecan-hziy; SG) vs. docetaxel in patients with metastatic or advanced NSCLC that had progressed on or after platinum-based chemotherapy and checkpoint inhibitor therapy.
Jan 16, 2024 10:00 am ET
Gilead Sciences with Emma's Story: Self-Advocacy in Breast Cancer
NORTHAMPTON, MA / ACCESSWIRE / January 16, 2024 / "It's an experience that I hope no one goes through, but it's an empowering experience."
Jan 10, 2024 11:10 am ET
Gilead Pays Tribute to Patient Advocacy Work: Cara’s Story
NORTHAMPTON, MA / ACCESSWIRE / January 10, 2024 / Gilead Sciences:
Jan 03, 2024 11:15 am ET
Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year
- Gilead Also Included on the Dow Jones Sustainability North America Index; Rankings Reflect Gilead's Ongoing Commitment to Corporate Responsibility -
Dec 21, 2023 04:05 pm ET
Gilead Sciences to Present at Upcoming Investor Conference
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference:
Dec 21, 2023 04:05 pm ET
U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy to Include Overall Survival Data
Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has approved a label update for Yescarta® (axicabtagene ciloleucel) to include the overall survival (OS) primary analysis from the landmark Phase 3 ZUMA-7 study showing a statistically significant improvement for Yescarta in OS versus standard of care (SOC) as second-line treatment with curative intent for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) within 12 months of completion of first-line therapy.
Dec 20, 2023 07:45 am ET
RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola
Investigational drugs opaganib and RHB-107 (upamostat) demonstrate distinct synergistic effect when combined individually with remdesivir, significantly improving potency while maintaining cell viability, in a new U.S. Army-funded and conducted in vitro Ebola virus study
Dec 19, 2023 08:15 am ET
Gilead Supports World Health Organization To Bolster Public Health in Bangladesh
NORTHAMPTON, MA / ACCESSWIRE / December 19, 2023 / We're proud to have contributed to this milestone announced by the World Health Organization - marking the elimination of visceral leishmaniasis (VL) as a public health problem in Bangladesh, the first country globally to eliminate this life-threatening, neglected tropical disease.
Dec 19, 2023 07:00 am ET
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, headquartered in Holon, Israel, to exclusively license its potential first-in-class, pre-clinical antibody program against IL-18 binding protein, incl
Dec 12, 2023 08:00 am ET
Gilead's Legal Team Achieves Rigorous Diversity Certification
NORTHAMPTON, MA / ACCESSWIRE / December 12, 2023 / Gilead SciencesOriginally published by Gilead Sciences
Dec 11, 2023 09:00 pm ET
Analyses of Kite’s Yescarta® CAR T-Cell Therapy Support Curative Potential in Patients With Non-Hodgkin Lymphomas
Kite, a Gilead Company (Nasdaq: GILD), today announced data from follow-up analyses of three studies of Yescarta® (axicabtagene ciloleucel) that demonstrate the long-term survival potential for patients living with several sub-types of relapsed or refractory (R/R) non-Hodgkin lymphoma, which were presented at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition. This included ZUMA-1 (Abstract #4864) showing that patients with refractory large B-cell lymphoma (LBCL) who maintained a complete response (CR) at 12- and 24-months following treatment with Y
Dec 11, 2023 07:30 pm ET
New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite’s Tecartus® in Patients With Aggressive Blood Cancers
Kite, a Gilead Company (Nasdaq: GILD), today announced the results of four new analyses supporting the use of Tecartus® (brexucabtagene autoleucel) in relapsed/refractory mantle cell lymphoma (R/R MCL) and relapsed/refractory adult B-cell precursor acute lymphoblastic leukemia (R/R B-ALL). These results include four-year overall survival (OS) data from the pivotal ZUMA-2 study and primary results from ZUMA-18, an expanded access study, evaluating the CAR T-cell therapy Tecartus in patients with R/R MCL that were presented orally (Abstract #106) at the 2023 American Society of Hemato
Dec 11, 2023 05:45 pm ET
Long-Term Data for Kite’s Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma
Kite, a Gilead Company (Nasdaq: GILD), today announced results from a three-year follow-up analysis of ZUMA-12, a Phase 2 study of Yescarta® (axicabtagene ciloleucel) as first-line treatment after two cycles of chemoimmunotherapy in patients with high-risk, large b-cell lymphoma (LBCL). The analysis, which demonstrated durability of clinical benefit – both high complete response (CR) and objective response rates (ORR), including in patients with MYC and BCL2 and/or BCL6 rearrangements (also known as double- or triple-hit histology) – was presented during an oral
Dec 11, 2023 12:00 pm ET
Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company has once again been recognized as one of the most sustainable pharmaceutical companies according to the Dow Jones Sustainability World Index (DJSI World) for the third consecutive year. The company was also included on the Dow Jones Sustainability North America Index (DJSI North America). These rankings are based on an in-depth analysis of Gilead’s sustainability performance and highlight the company’s longstanding sustainable business practices and transparency on environmental, social and governance (ESG) issues.
Dec 06, 2023 09:05 pm ET
Gilead's Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023
FOSTER CITY, Calif. / ACCESSWIRE / December 6, 2023 / Gilead Sciences, Inc. (NASDAQ:GILD) announced it will present new data at San Antonio Breast Cancer Symposium (SABCS) 2023, supporting the use of Trodelvy® (sacituzumab govitecan-hziy) in certain metastatic triple-negative breast cancer (mTNBC) and pre-treated HR+/HER2- metastatic breast cancer (mBC) patients.
Dec 01, 2023 03:15 pm ET
Gilead Employees Stitch Together To Create a Special Panel of the AIDS Quilt
NORTHAMPTON, MA / ACCESSWIRE / December 1, 2023 / Nearly 36 years ago the AIDS Memorial Quilt was displayed for the first time to memorialize and physically represent lives lost to HIV. Gilead has always actively supported the Quilt, and creating a new panel made sense for a company dedicated to helping end the HIV epidemic for everyone, everywhere.
Nov 30, 2023 08:30 am ET
Gilead’s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023
Gilead Sciences, Inc. (Nasdaq: GILD) today announced it will present new data at San Antonio Breast Cancer Symposium (SABCS) 2023, supporting the use of Trodelvy® (sacituzumab govitecan-hziy) in certain metastatic triple-negative breast cancer (mTNBC) and pre-treated HR+/HER2- metastatic breast cancer (mBC) patients.
Nov 28, 2023 08:15 am ET
Gilead's Ambition: To Help End the HIV Epidemic
NORTHAMPTON, MA / ACCESSWIRE / November 28, 2023 / "At Gilead, we have a bold ambition: We'd like to help end the HIV epidemic for everyone, everywhere and we know you cannot do that alone," shared Janet Dorling, Senior Vice President, Intercontinental Region and Global Patient Solutions.
Nov 21, 2023 08:25 am ET
Gilead Sciences: Breaking Barriers to Breast Cancer Care in Rural Areas
NORTHAMPTON, MA / ACCESSWIRE / November 21, 2023 / Gilead Sciences
Nov 15, 2023 06:00 am ET
Kite and Arcellx Announce Expansion in Strategic Partnership
Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced that the companies have expanded their existing collaboration, which was originally announced i
Nov 15, 2023 05:00 am ET
ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP
-- Arcellx to receive $200M equity investment at $61.68 per share and an $85 million upfront cash payment --
Nov 14, 2023 08:45 am ET
Gilead Named Number One Overall Philanthropic Funder of HIV-Related Programs for Second Year in a Row by Funders Concerned About AIDS
- The New Report Also Recognized Gilead As the Number One Funder of Organizations Focused on Achieving Health Equity for Key Populations, Including U.S. BIPOC Communities, Transgender Communities and Gay Men -
Nov 09, 2023 09:00 am ET
Gilead Sciences: Research Scholars Program Scientists Advancing HIV Research
NORTHAMPTON, MA / ACCESSWIRE / November 9, 2023 / Gilead Sciences / Dr. Shringar Rao's inquisitive nature and dedication to addressing health inequities drive her eagerness to help advance innovative scientific breakthroughs. Even as an early-career researcher, she has a distinct and ambitious mission - to not lose anyone to a preventable HIV-related death - and is working with numerous other researchers in support of this goal.
Nov 08, 2023 07:13 pm ET
Gilead Sciences to Present at Upcoming Investor Conferences
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:
Nov 07, 2023 04:02 pm ET
Gilead Sciences Announces Third Quarter 2023 Financial Results
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter of 2023.
Nov 07, 2023 09:30 am ET
Gilead Sciences: Advancing Global Health Equity in Tropical Regions
NORTHAMPTON, MA / ACCESSWIRE / November 7, 2023 / Gilead Sciences / In the late 1980s, people in Dr. Shyam Sundar's homeland in eastern India were dying by the hundreds of thousands of a debilitating parasitic disease known as visceral leishmaniasis (VL).
Nov 06, 2023 05:00 pm ET
Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced that domvanalimab plus zimberelimab and chemotherapy showed encouraging overall response rate (ORR) and six-month progression-free survival (PFS) rate results in a preliminary analysis from Arm A1 of the EDGE-Gastric study. This ongoing Phase 2, multi-arm, global study is evaluating the safety and efficacy of various combinations of the Fc-silent anti-TIGIT antibody domvanalimab plus the anti-PD-1 antibody zimberelimab and chemotherapy in patients with locally advanced unresectable or metastatic gastr
Nov 06, 2023 05:00 pm ET
Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced that domvanalimab plus zimberelimab and chemotherapy showed encouraging overall response rate (ORR) and six-month progression-free survival (PFS) rate results in a preliminary analysis from Arm A1 of the EDGE-Gastric study. This ongoing Phase 2, multi-arm, global study is evaluating the safety and efficacy of various combinations of the Fc-silent anti-TIGIT antibody domvanalimab plus the anti-PD-1 antibody zimberelimab and chemotherapy in patients with locally advanced unresectable or metastatic gastr
Nov 03, 2023 11:00 am ET
Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting® 2023
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new viral hepatitis data at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, from November 10-14, 2023. Key findings from more than 80 presentations will include a late-breaker oral presentation of primary endpoint results from the Phase 2b MYR204 study evaluating Hepcludex® (bulevirtide), an investigational therapy in the U.S. and outside of the European Economic Area, in combination with pegylated interferon alfa-2a (PegIFNα) in patients with chronic hepatitis de
Nov 02, 2023 09:15 am ET
Gilead and Kite Oncology Present Data Demonstrating Car T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023
Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will share 29 presentations, including 10 oral presentations, during the 65th American Society of Hematology (ASH) Annual Meeting and Exposition (December 9-12).
Oct 31, 2023 08:20 am ET
Gilead's Commitment to Advancing Health Equity for Black Women and Ending the HIV Epidemic
NORTHAMPTON, MA / ACCESSWIRE / October 31, 2023 / Before I came to Gilead, I knew it as a company that produces innovative therapies across HIV, liver disease and cancer. Now I know it's so much more. Its focus goes well beyond medicine - and at its heart, Gilead is a company that lives and breathes a commitment to health equity.
Oct 31, 2023 07:30 am ET
Kite and Epic Bio Announce Collaboration to Develop New Therapies for Cancer
Kite, a Gilead Company (Nasdaq: GILD) and Epicrispr Biotechnologies (“Epic Bio”), today announced the companies have entered into a research collaboration and license agreement using Epic Bio’s proprietary gene regulation platform to develop next-generation cancer cell therapies. The agreement will allow Kite to leverage the licensed technology to modulate certain genes to potentially enhance CAR T-cell functionality.
Oct 24, 2023 12:00 pm ET
Gilead Named Number One Overall Philanthropic Funder of HIV-Related Programs for Second Year in a Row by Funders Concerned About AIDS
Gilead Sciences, Inc. (Nasdaq: GILD) today was recognized as the number one philanthropic funder of HIV-related programs for the second year in a row, in a new report released by Funders Concerned About AIDS (FCAA). FCAA’s annual Philanthropic Support to Address H
Oct 20, 2023 05:10 am ET
New Data Presented at EACS 2023 Further Demonstrate Strong Clinical Profile of Twice-Yearly Sunlenca® for Adults With Multi-Drug Resistant HIV
Gilead Sciences, Inc. (Nasdaq: GILD) presented new data today supporting Sunlenca® (lenacapavir) as an important treatment option for adults with multi-drug resistant (MDR) HIV who have extensive treatment history. These findings highlight the significance of lenacapavir, the first long-acting injectable HIV treatment medication administered twice-yearly, as a person-centric therapy option and its potential to help transform the future of coordinated HIV clinical care. The data were presented at the 19th European AIDS Conference (
Oct 19, 2023 03:00 am ET
Real-World Evidence Reinforces Biktarvy® as a Long-Term Treatment Option With a High Barrier to Resistance for People With HIV and a Range of Comorbidities
Gilead Sciences, Inc. (Nasdaq: GILD) announced today new long-term real-world data from the BICSTaR study highlighting the safety and efficacy profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) as a treatment regimen for a broad range of people with HIV, including those with a prior treatment history or comorbidities. These findings were presented at the 19th European AIDS Conference (
Oct 18, 2023 03:00 am ET
Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program
Gilead Sciences, Inc. (Nasdaq: GILD) today announced PURPOSE 5, the first Phase 2 clinical trial to evaluate an investigational long-acting HIV prevention option in Europe. The study will assess the persistence—defined as consistent and continuous use—of lenacapavir compared with emtricitabine/tenofovir disoproxil fumarate (F/TDF) in people who may benefit from pre-exposure prophylaxis (PrEP) and who are not currently taking PrEP. The study has an intentional focus on recruiting participants from groups across France and the United Kingdom that are disproportionally affected by HIV and often u
Oct 17, 2023 09:30 am ET
Gilead Sciences: Leading With Passion and Purpose: Sandra’s Story
NORTHAMPTON, MA / ACCESSWIRE / October 17, 2023 / Gilead Sciences / Many teenagers have some idea of what they want to do for a career - but few are as crystal clear as Sandra Patterson was. From a young age in Guatemala, Sandra was naturally good at math and accounting, and decided she wanted to spend her life using them to solve complex issues.
Oct 17, 2023 07:00 am ET
Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases
Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that the companies have entered into a 12-year partnership to advance the research and development of novel antiviral therapies, with an initial focus in Assembly Bio’s established areas of herpesviruses, hepatitis B virus (HBV) and hepatitis D virus (HDV).
Oct 16, 2023 07:30 am ET
Gilead and Kite Oncology Present Important New Data Across Multiple Difficult-to-Treat Cancers at ESMO Congress 2023
Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present new data, including three oral presentations, at the European Society for Medical Oncology (ESMO) Congress 2023. New clinical data for Trodelvy® (sacituzumab govitecan-hziy) continue to support its use in metastatic triple-negative breast cancer (mTNBC) and pre-treated HR+/HER2- metastatic breast cancer (mBC) and demonstrate the expanding body of evidence for Trodelvy in small cell lung cancer and head and neck cancer. Kite will also present analyses supporting the use of Yescarta® (axicabtagene
Oct 16, 2023 01:01 am ET
Gilead Demonstrates the Impact of Global Collaboration in Advancing HIV Research and Health Equity at EACS 2023
Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the 19th European AIDS Conference (EACS) to be held in Warsaw, Poland from October 18-21, 2023. As a leader in HIV innovation, Gilead will provide an update on its signature initiatives, key collaborations and share new scientific data from its HIV research and development
Oct 12, 2023 04:05 pm ET
Gilead Sciences to Release Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2023 financial results and guidance will be released on Tuesday, November 7, 2023 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s third quarter 2023 financial results and provide a business update.
Oct 12, 2023 09:00 am ET
Global CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032
FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell...
Oct 03, 2023 08:30 am ET
Gilead to Present Latest Innovative Virology Data on Current and Potentially Transformative Therapies Across HIV and COVID-19 at IDWeek 2023
Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from its virology research and development programs that will be presented at IDWeek 2023, October 11-15 in Boston. These latest data demonstrate the company’s ongoing efforts to address the unmet medical needs of people and communities affected by HIV and COVID-19. Gilead will be presenting 16 abstracts, including real-world evidence, as the company continues to pursue the next wave of scientific discovery in virology.
Oct 02, 2023 09:00 am ET
Gilead Board Director Kevin E. Lofton Named to List of Influential Leaders
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Kevin E. Lofton, Lead Independent Director, has been named one of the most influential leaders in corporate governance by the National Association of Corporate Directors (NACD) as part of their 2023 NACD Directorship 100™, an annual list of leading corporate directors and governance advocates.
Sep 19, 2023 08:30 am ET
CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Hepatic Impairment
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) granted a positive opinion for the use of Veklury® (remdesivir) to treat people with COVID-19 with mild to severe hepatic impairment. The European Commission (EC) will review the CHMP recommendation and, if adopted, Veklury will become the first and only authorized antiviral COVID-19 treatment that can be used across all stages of liver disease.
Sep 18, 2023 04:00 am ET
Kite’s Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cel
Kite, a Gilead Company (Nasdaq: GILD), today announced results from the Phase 2 ALYCANTE study, led and sponsored by the French collaborative group LYSA/LYSARC, for use of its chimeric antigen receptor (CAR) T-cell therapy Yescarta® (axicabtagene ciloleucel) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after one prior line of therapy who were deemed ineligible for high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT). The full findings from the study were published in
Sep 10, 2023 03:01 am ET
Gilead’s Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell
Gilead Sciences, Inc. (Nasdaq: GILD) today announced promising early data from the global, open-label, Phase 2 EVOKE-02 study evaluating Trodelvy® (sacituzumab govitecan-hziy) in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) with or without platinum agents in patients with previously untreated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations. The results are being presented today at the IASLC 2023 World Conference on Lung Cancer (#WCLC23) hosted by the International Association for the Study of Lung Ca
Sep 07, 2023 08:55 pm ET
Gilead Prices $2 Billion of Senior Unsecured Notes
Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an aggregate principal amount of $2 billion, in an underwritten, registered public offering, consisting of $1 billion of 5.250% senior notes maturing in 2033 and $1 billion of 5.550% senior notes maturing in 2053. The offering is expected to close September 14, 2023, subject to customary closing conditions.
Sep 06, 2023 09:30 am ET
Gilead Sciences: How One School Has Transformed Education for First-Generation Students
NORTHAMPTON, MA / ACCESSWIRE / September 6, 2023 / As an elementary school student, Nohely Peraza took a bus from her home in East Palo Alto to a school several miles away in another city. The local commute program sought to address the lack of diversity in schools in high-income neighborhoods and create educational opportunities for those in lower-income areas. For Nohely, it felt like a different world - the houses were bigger, and the surrounding area was far less racially diverse than the neighborhood she lived in.
Aug 30, 2023 08:45 am ET
Gilead Sciences: Fifth Anniversary of COMPASS: Helping Address the HIV Epidemic in the U.S. South
NORTHAMPTON, MA / ACCESSWIRE / August 30, 2023 / This year marks the fifth anniversary of the Gilead COMPASS Initiative®, a 10-year, more than $100 million commitment to addressing the HIV epidemic in the Southern United States.
Aug 24, 2023 08:30 am ET
FDA Approves Veklury® (Remdesivir) to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose Adjustment
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) for the use of Veklury® (remdesivir) with no dose adjustments to treat COVID-19 in people with mild, moderate and severe hepatic impairment. This approval further supports the safety profile of Veklury as the first and only approved antiviral COVID-19 treatment that can be used across all stages of liver disease.
Aug 23, 2023 04:05 pm ET
Gilead Sciences to Present at Upcoming Investor Conferences
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:
Aug 23, 2023 08:45 am ET
How Gilead’s Pharmaceutical Development and Manufacturing Team Delivers Transformative Medicines
NORTHAMPTON, MA / ACCESSWIRE / August 23, 2023 / Gilead Sciences
Aug 21, 2023 08:30 am ET
Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the initiation of new patients in U.S. studies evaluating magrolimab to treat acute myeloid leukemia (AML).
Aug 18, 2023 12:00 pm ET
Gilead Sciences and Meharry Medical College Highlight Five-Year Impact of Gilead COMPASS Initiative® on HIV in the Southern United States
Gilead Sciences, Inc. (Nasdaq: GILD) and Meharry Medical College, one of the nation’s oldest and largest historically Black academic health science centers, today announced the publication of a new supplemental issue of Meharry Medical College’s Journal of Health Care for the Poor and Underserved. It details the impact of the Gilead COMPASS Initiative® – the company’s 10-year, more than $100 million collaborative initiative that seeks to eradicate underlying serious and systemic challenges that contribute to the HIV epidemic in the Southern United States.
Aug 16, 2023 08:00 am ET
Gilead’s Focus on Ending the HIV Epidemic for Children Everywhere
NORTHAMPTON, MA / ACCESSWIRE / August 16, 2023 / Gilead Sciences
Aug 15, 2023 08:30 am ET
Gilead and Tentarix to Discover and Develop Novel Therapies to Address Unmet Medical Needs Across Cancer and Inflammation
Gilead Sciences, Inc. (Nasdaq:GILD) and Tentarix Biotherapeutics today announced that the companies established three multi-year collaborations leveraging Tentarix’s proprietary Tentacles™ platform to discover and develop multi-functional, conditional protein therapeutics for oncology and inflammatory diseases. Designed to enhance both therapeutic benefit and safety, these molecules have the potential to conditionally target immune cells related to disease pathways without activating other immune cells that may create adverse events.
Aug 09, 2023 08:05 am ET
Gilead Sciences: A Cut Above the Rest: Innovative Barbershop Program Educates Indigenous Men About HIV
NORTHAMPTON, MA / ACCESSWIRE / August 9, 2023 / Gilead Sciences:
Aug 03, 2023 04:02 pm ET
Gilead Sciences Announces Second Quarter 2023 Financial Results
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter of 2023.
Aug 02, 2023 01:55 pm ET
Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities
FOSTER CITY, CA / ACCESSWIRE / August 2, 2023 / Gilead Sciences Inc. (Nasdaq:GILD) announced its largest commitment to health equity for Australian and Canadian Indigenous communities. The initiative will support programs addressing societal barriers to care that persistently contribute to the transmission of HIV and viral hepatitis within Indigenous communities.
Jul 27, 2023 01:23 pm ET
European Commission Approves Gilead’s Trodelvy® For Pre-Treated HR+/HER2- Metastatic Breast Cancer
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) approved Trodelvy® (sacituzumab govitecan) as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting.
Jul 24, 2023 07:00 pm ET
Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV
Gilead Sciences, Inc. (Nasdaq: GILD) today presented new data reinforcing the efficacy, safety, and tolerability profile of lenacapavir, including patient-reported outcomes (PRO) from the Phase 2/3 CAPELLA trial. These latest findings underscore the role of lenacapavir, the first long-acting injectable HIV treatment medication administered twice-yearly, as a person-centric therapy option and its transformative potential impact on the future of coordinated HIV clinical care. The data were presented at the 12th International AIDS Society (IAS) Conference on HIV Science (IAS 2023), taking place J
Jul 24, 2023 08:00 am ET
Cognizant and Gilead Extend Partnership with Five-Year Service Agreement Estimated at $800 Million
Cognizant will manage Gilead's global IT infrastructure while leading digital transformation initiatives designed to enhance overall client experience and enable faster time to market for Gilead products.
Jul 23, 2023 09:51 pm ET
New Biktarvy® Data Presented at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic
Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from multiple studies reinforcing Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) as a treatment option for a broad range of people with HIV. The latest findings include key insights into the treatment of virologically suppressed pregnant women and children two years of age or older (weighing at least 14 kg to less than 25 kg) and positive Week 96 data from the ALLIANCE trial in adults with HIV/hepatitis B (HBV) coinfection who were initiating therapy. The data were presented
Jul 23, 2023 05:00 pm ET
Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities
Gilead Sciences Inc. (Nasdaq: GILD) today announced its largest commitment to health equity for Australian and Canadian Indigenous communities. The initiative will support programs addressing societal barriers to care that persistently contribute to the transmission of HIV and viral hepatitis within Indigenous communities.
Jul 21, 2023 05:02 pm ET
Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes (MDS) has been discontinued due to futility based on a planned analysis. The safety data seen in this study is consistent with the known magrolimab profile and adverse events that are typical in this patient population. Gilead recommends discontinuing treatment with magrolimab in patients with MDS. Magrolimab is a potential first-in-class, anti-CD47 immunotherapy with a clinical development program spanning ten potential indications including ongoing trials in solid tumo
Jul 20, 2023 12:00 pm ET
Center for Disease Analysis Foundation Announces Receipt of an $8 Million Grant from Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States
The Center for Disease Analysis Foundation (CDA Foundation) announced today that it received an $8 million grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant program. CDA Foundation will disperse the grant to qualifying...
Jul 20, 2023 12:00 pm ET
Center for Disease Analysis Foundation Announces Receipt of an $8 Million Grant From Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States
The Center for Disease Analysis Foundation (CDA Foundation) announced today that it received an $8 million grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant program. CDA Foundation will disperse the grant to qualifying tax-exempt organizations to contact diagnosed but untreated patients with hepatitis C virus (HCV) or hepatitis B virus (HBV) infection to bring them back into care.
Jul 20, 2023 12:00 pm ET
Gilead Announces $8 Million in Grant Funding for Viral Hepatitis Relink Program in the U.S.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is providing a total of $8 million in funding through a new grant program in the United States called Gilead Relink, which is focused on bringing diagnosed but untreated people living with hepatitis C virus (HCV) or hepatitis B virus (HBV) back into care. The CDA Foundation (CDAF), based in Lafayette, Colorado, will act as the lead organization for the program and be responsible for implementing and overseeing Gilead Relink, including distributing funds to grantees identified by CDAF that meet certain criteria, integral strategic planning
Jul 19, 2023 10:15 am ET
Gilead Sciences: Putting a Spotlight on the Mental Health Needs of LGBTQ+ Youth
NORTHAMPTON, MA / ACCESSWIRE / July 19, 2023 / Across the country, LGBTQ+ youth face challenges that are negatively affecting their mental health. Some find themselves not feeling accepted by their family or friends, or being verbally harassed at school. Many are affected by a slew of new bills that regulate everything from what bathrooms individuals can use to whether people have access to gender-affirming healthcare.
Jul 19, 2023 08:30 am ET
Gilead Showcases Latest HIV Pipeline Progress and the Impact of Global Collaboration on Health Equity Efforts at IAS 2023
Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming contributions to the 12th International AIDS Society Conference on HIV Science (IAS 2023), taking place in Brisbane, Australia, and virtually, from July 23-26, 2023. As the leader in HIV innovation, Gilead will provide updates on its signature initiatives and key collaborations while sharing new scientific data from its research and development programs. The breadth of data presented at the meeting, along with Gilead-led symposia, reflect its innovative approach to advancing HIV prevention, treatment and cure strategies and unde
Jul 14, 2023 04:05 pm ET
Gilead Sciences to Release Second Quarter 2023 Financial Results on Thursday, August 3, 2023
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2023 financial results and guidance will be released on Thursday, August 3, 2023 after the market closes. At 5:00 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s second quarter 2023 financial results and provide a business update.
Jul 14, 2023 08:00 am ET
FDA Approves Veklury® (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) for the use of Veklury® (remdesivir) in COVID-19 patients with severe renal impairment, including those on dialysis. With this approval, Veklury is now the first and only approved antiviral COVID-19 treatment that can be used across all stages of renal disease. More than 1 in 7 (37 million) people in the U.S. are estimated to have chronic kidney disease (CKD) and are at increased risk of COVID-19 related morbidity and mortality. Th
Jul 13, 2023 06:00 am ET
Gilead Partners with CHAI and Penta to Improve Treatment and Adherence Rates Among Children with HIV in Low and Middle Income Countries
Gilead Sciences, Inc. (Nasdaq: GILD) is pleased to announce two public-private partnerships. The first will accelerate the development of an investigational dispersible pediatric formulation containing emtricitabine and tenofovir alafenamide (F/TAF). The second aims to develop investigational pediatric formulations of TAF and sofosbuvir (SOF) designed to eliminate bitterness.
Jun 23, 2023 08:11 am ET
Gilead Receives CHMP Positive Opinion for Trodelvy® in Pre-Treated HR+/HER2- Metastatic Breast Cancer
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Trodelvy® (sacituzumab govitecan) as monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting. The final European Commission decision on the additional indication for Trodelvy is anticipated later in
Jun 23, 2023 02:30 am ET
Hepcludex® (Bulevirtide) Demonstrates Sustained Efficacy and Safety Profile in People With Chronic Hepatitis Delta Virus at 96 Weeks
Gilead Sciences, Inc. (Nasdaq: GILD) today announced Week 96 results from the pivotal MYR301 Phase 3 clinical trial evaluating the first-in-class entry inhibitor Hepcludex® (bulevirtide) for the treatment of adults with chronic hepatitis delta (HDV) infection. These new data presented at the European Association for the Study of the Liver (EASL) Congress 2023 reinforce the role of bulevirtide as an efficacious and well-tolerated treatment for the management of chronic HDV. Bulevirtide remains the only approved treatment for HDV in the EU and is not approved in the U.S.
Jun 22, 2023 08:30 am ET
Kite Announces Completion of Marketing Authorization Transfer for Yescarta® CAR T-cell Therapy in Japan
Kite Pharma, Inc., a Gilead Company (Nasdaq: GILD), today announced that the Marketing Authorization in Japan for Yescarta® (axicabtagene ciloleucel), a chimeric antigen receptor (CAR) T-cell therapy, has been transferred from Daiichi Sankyo Co., Ltd. to Gilead Sciences K.K., the Japan subsidiary of Gilead Sciences, Inc.
Jun 21, 2023 08:15 am ET
Gilead Sciences Supports the LGBTQ+ Community in Oakland: Love Is the Answer
NORTHAMPTON, MA / ACCESSWIRE / June 21, 2023 / Gilead Sciences:
Jun 14, 2023 08:15 am ET
Asian American Women Engineers Find Community and Purpose at Gilead
NORTHAMPTON, MA / ACCESSWIRE / June 14, 2023 / Gilead Sciences
Jun 14, 2023 03:00 am ET
Gilead to Present Latest Liver Disease Research at the European Association for the Study of the Liver (EASL) Congress 2023
Gilead Sciences, Inc. (Nasdaq:GILD) today announced new data to be presented at the European Association for the Study of the Liver (EASL) Congress 2023, June 21-24, 2023. Key findings from more than 70 presentations will include Week 96 data from the pivotal Phase 3 study of Hepcludex® (bulevirtide) evaluating the efficacy and safety for the treatment of hepatitis delta virus (HDV) and late-breaking data on the impact of continued treatment with bulevirtide. Gilead will also present real-world data on efforts that support the World Health Organization’s (WHO) goal of eliminating vi
Jun 07, 2023 09:45 am ET
Gilead Sciences: Living with a Rare Blood Cancer: Marion’s Story
NORTHAMPTON, MA / ACCESSWIRE / June 7, 2023 / Marion grew up very healthy, never even getting colds or the flu - but that changed as she got older.
Jun 06, 2023 10:45 am ET
Kite’s Tecartus® CAR T-cell Therapy Demonstrates 78% Complete Response Rate and 90% Overall Response Rate in Largest Real-World Evidence Analysis for Relapsed/Refractory Mantle Cell Lymphoma
Kite, a Gilead Company (Nasdaq: GILD), today announces findings from the largest real-world analysis to date of Tecartus® (brexucabtagene autoleucel) in patients with relapsed or refractory mantle cell lymphoma (R/R MCL), which show that outcomes of Tecartus therapy had consistent high complete response (CR) and overall response rates (ORR), regardless of type of prior treatment, including: Bruton's tyrosine kinase inhibitor (BTKi), bendamustine or autologous hematopoietic cell transplant (autoHCT). Higher CR was seen when Tecartus was given as second-and-third-line compared to late
Jun 05, 2023 12:30 pm ET
Trodelvy® Continues to Show Durable Overall Survival Advantage in Pre-Treated HR+/HER2- Metastatic Breast Cancer
Gilead Sciences, Inc. (Nasdaq: GILD) today announced longer-term overall survival (OS) results from the Phase 3 TROPiCS-02 study evaluating Trodelvy® (sacituzumab govitecan-hziy) versus comparator chemotherapy (physicians’ choice of chemotherapy, TPC) in patients with HR+/HER2- (IHC0, IHC1+, IHC2+/ISH-) metastatic breast cancer who received endocrine-based therapies and at least two chemotherapies. In this exploratory analysis, Trodelvy demonstrated a clinically meaningful improvement in median OS benefit compared to TPC (median OS: 14.5 months vs. 11.2 months; hazard ratio (HR): 0.
Jun 05, 2023 11:25 am ET
Kite’s Yescarta® CAR T-cell Therapy Demonstrates Significantly Longer Overall Survival Versus Standard of Care as Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
Kite, a Gilead Company (Nasdaq: GILD), today announces detailed results from the overall survival (OS) analysis of the landmark Phase 3 ZUMA-7 study of Yescarta® (axicabtagene ciloleucel [axi-cel]) CAR T-cell therapy compared with historical standard of care (SOC) as initial treatment in the curative setting for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL). Yescarta is the first treatment in nearly 30 years to demonstrate a significant improvement in survival in this patient population. The late-breaking data are being presented orally at the 2023 American S
Jun 03, 2023 01:30 pm ET
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced updated results from an interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations. ARC-7 is the first Phase 2, randomized, open-label study evaluating the combinations of Fc-silent anti-TIGIT monoclonal antibody domvanalimab plus anti-PD-1 monoclonal antibody zimberelimab (doublet) and domvanalimab plus zimbereli
Jun 01, 2023 08:34 am ET
Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA
Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 17 abstracts from its industry-leading cell therapy portfolio and growing blood cancer pipeline at the upcoming 2023 European Hematology Association (EHA) Annual Congress being held in Frankfurt, Germany, June 8-11, and virtually June 14-15.
May 31, 2023 10:45 am ET
Bilal Piperdi on How Gilead Is Striving To Create New Possibilities for People With Lung Cancer
NORTHAMPTON, MA / ACCESSWIRE / May 31, 2023 / After finishing medical school in the late 1990s, Bilal Piperdi wanted to follow his mentor into the field of thoracic oncology, the specialized area that focuses on lung cancer. Yet many of his peers and friends discouraged him due to its many challenges, including a lack of promising options for patients.
May 26, 2023 01:00 am ET
CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Severe Renal Impairment, Including Those on Dialysis
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) granted a positive opinion for the use of Veklury® (remdesivir) in COVID-19 patients with severe renal impairment, including those on dialysis. The European Commission (EC) will review the CHMP recommendation and, if adopted, Veklury will become the first and only authorized antiviral COVID-19 treatment that can be used across all stages of renal disease.
May 25, 2023 04:05 pm ET
Gilead Sciences to Present at Upcoming Investor Conference
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference:
May 25, 2023 09:40 am ET
How Gilead’s Supportive Culture Helps Working Parents: LJ’s Story
NORTHAMPTON, MA / ACCESSWIRE / May 25, 2023 / Gilead Sciences
May 17, 2023 08:30 am ET
Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care at ASCO 2023
Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 30 abstracts during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. These data reinforce the strength of Gilead and Kite Oncology’s transformative science in hard-to-treat cancers.
May 16, 2023 04:01 pm ET
Gilead Appoints Cindy Perettie Executive Vice President of Kite
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Cindy Perettie will join the company as Executive Vice President of Kite, a Gilead Company, overseeing the cell therapy business, and will become a member of Gilead’s senior leadership team, effective May 30.
May 15, 2023 08:30 am ET
Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced that the companies have expanded the previously announced
May 15, 2023 08:30 am ET
Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation
Gilead Sciences, Inc. (Nasdaq:GILD) and Arcus Biosciences, Inc. (NYSE:RCUS) today announced that the companies have expanded the previously announced
May 10, 2023 08:25 am ET
Gilead Emphasizes Unique Ways To Hire Top Talent
NORTHAMPTON, MA / ACCESSWIRE / May 10, 2023 / When Jamari Brooks was looking for a new job last fall, he knew he wanted his future employer to have a few key qualities. As he perused pharmaceutical companies' job postings, he kept a look out for diversity in leadership, the potential for personal career growth and a commitment to helping improve the lives of people and the health of the world.
May 09, 2023 08:30 am ET
Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the acquisition of all outstanding shares of XinThera, a privately held biotech company in San Diego. The acquisition complements Gilead’s existing clinical development priorities by adding additional pipeline assets for well-validated targets in oncology and inflammation.
May 04, 2023 07:00 am ET
CHMP Adopts Positive Opinion Recommending Hepcludex® (Bulevirtide) for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus (HDV)
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Hepcludex® (bulevirtide) for the treatment of adults with chronic HDV and compensated liver disease, and recommended granting full Marketing Authorisation (MA) that is no longer subject to specific obligations. Bulevirtide was initially granted conditional marketing authorisation in July 2020 to provide people living with HDV urgent access to treatment. The CHMP recommendation for full Marketing
May 03, 2023 08:20 am ET
Gilead Remains Steadfast in Support for Hepatitis C Elimination Efforts
FOSTER CITY, CA / ACCESSWIRE / May 3, 2023 / The recent national conversation on hepatitis C (HCV) is an encouraging step towards viral hepatitis elimination in the U.S. With its long history of leadership in viral hepatitis, Gilead continues to support efforts that focus on HCV elimination. Gilead is proud that its medicines have treated over four million individuals living with HCV globally. Today, some 2.4 million people are living with HCV in the U.S., even though ~95% of those treated with direct-acting antivirals (DAAs) are cured. Prices of HCV medicines have dropped sig
May 01, 2023 04:05 pm ET
Gilead Sciences to Present at Upcoming Investor Conferences
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:
Apr 27, 2023 04:02 pm ET
Gilead Sciences Announces First Quarter 2023 Financial Results
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter of 2023.
Apr 24, 2023 05:05 pm ET
Gilead Sciences Releases Inaugural ESG Impact Report
NORTHAMPTON, MA / ACCESSWIRE / April 24, 2023 / Gilead Sciences recently released its inaugural Environmental, Social and Governance (ESG) Impact Report. This is an evolution of our traditional Year in Review, and uses the ESG framework to highlight the successes and achievements of the prior year.
Apr 19, 2023 08:55 am ET
Gilead Sciences: Breaking Down Barriers To Access in HIV and Beyond: A Perspective
NORTHAMPTON, MA / ACCESSWIRE / April 19, 2023 / Gilead Sciences
Apr 16, 2023 04:00 am ET
Veklury® (Remdesivir) Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations
Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive results from several COVID-19 clinical and real-world evidence studies being presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). A Phase 3 clinical study demonstrated that Veklury® (remdesivir) was generally well tolerated in people with moderate to severe renal impairment. Additional data includes a retrospective real-world study which demonstrated that Veklury treatment is associated with a lower risk of death from COVID-19 for people living with cancer. A separate real-world
Apr 13, 2023 04:05 pm ET
Gilead Sciences to Release First Quarter 2023 Financial Results on Thursday, April 27, 2023
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2023 financial results will be released on Thursday, April 27, 2023 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s first quarter 2023 financial results and provide a business update.
Apr 12, 2023 08:25 am ET
Gilead Sciences: 4 Questions: Global Experts Convene To Identify Key Measures to Long-Term Success in HIV
NORTHAMPTON, MA / ACCESSWIRE / April 12, 2023 / Gilead Sciences:
Apr 05, 2023 08:30 am ET
Gilead Sciences: Overcoming COVID-19 in Early 2020: Keith’s Story
NORTHAMPTON, MA / ACCESSWIRE / April 5, 2023 / Early in 2020, Keith Prowell was making the most of his retirement in New York and staying active with swimming and tai chi. But as reports of a new, unknown virus started spreading, he began not feeling well.
Mar 29, 2023 10:35 am ET
Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. Communities
Originally Published by Gilead Sciences
Mar 22, 2023 12:00 pm ET
Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. Communities
Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is providing a total of $3 million in grant funding to eight organizations to provide services to communities disproportionately impacted by HIV in rural areas in the United States. My Brother’s Keeper, based in Ridgeland, Mississippi, will provide technical assistance and capacity building to the organizations funded through this initiative. These grants are part of Gilead’s ongoing Zeroing In™ program to help end the HIV epidemic by supporting organizations working to improve the overall health and wellness of communities most impacted
Mar 21, 2023 09:37 am ET
Kite’s Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
Kite, a Gilead Company (Nasdaq: GILD), today announced the primary overall survival (OS) analysis results of the Phase 3 ZUMA-7 study. The results showed a statistically significant improvement for Yescarta in OS versus historical treatment, which was the standard of care (SOC) in a curative setting for nearly 30 years, for initial treatment of adult patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) within 12 months of completion of first-line therapy. Historical SOC is a multi-step process involving platinum-based salvage combination chemoimmunotherapy regimen followed by hig
Mar 20, 2023 08:30 am ET
Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479
Gilead Sciences, Inc. (Nasdaq: GILD) and Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation therapies, today announced that Gilead has exercised its option to exclusively...
Mar 20, 2023 08:30 am ET
Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479
Gilead Sciences, Inc. (Nasdaq: GILD) and Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation therapies, today announced that Gilead has exercised its option to exclusively license Nurix’s investigational targeted protein degrader molecule NX‑0479. This bivalent degrader, designated GS-6791, is the first development candidate resulting from the
Feb 22, 2023 11:21 am ET
Gilead Presents Positive Proof-of-Concept Data for Investigational Combination Regimen of Lenacapavir with Broadly Neutralizing Antibodies as a Potential Twice-Yearly Approach for the Treatment of HIV
Gilead Sciences, Inc. (Nasdaq: GILD) today announced data evaluating lenacapavir in combination with broadly neutralizing antibodies (bNAbs) teropavimab and zinlirvimab as a potential long-acting treatment regimen with twice-yearly dosing. Results from the Phase 1b clinical trial demonstrated the investigational combination was generally well tolerated with high efficacy in select virologically suppressed participants living with HIV. These data were presented at the 30th Conference on Retroviruses and Opportunistic Infections (CROI).
Feb 22, 2023 09:00 am ET
Kite Completes Acquisition of Tmunity
Kite, a Gilead Company (NASDAQ: GILD), today announced the completion of the previously announced transaction to acquire Tmunity Therapeutics (Tmunity), a clinical-stage, private biotech company focused on next-gener
Feb 21, 2023 05:30 pm ET
Veklury® (Remdesivir) Reduced Risk of Mortality in Hospitalized COVID-19 Patients Across all Variant Time Periods in a Real World Study of More than 500,000 Hospitalized Patients
Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive data from three retrospective real-world studies which demonstrated that initiation of Veklury® (remdesivir) within the first two days of hospital admission can help reduce mortality and hospital readmission rates among all patients hospitalized with COVID-19, regardless of disease severity. A reduction in mortality was also observed in vulnerable populations, such as people living with cancer or HIV. These studies evaluated routine clinical practice data from more than 800 hospitals throughout the United States to gain i
Feb 21, 2023 03:01 pm ET
Gilead Presents New Data From HIV Cure Research Program and Collaborations Exploring Novel Investigational Combinations and Strategies
Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from four collaborative studies evaluating novel investigational combinations and strategies with the potential to target the HIV viral reservoir or enhance immune response to maintain virologic control in the absence of antiretroviral therapy (ART). These latest findings represent an ongoing multi-pronged approach in Gilead’s HIV cure research program. The data were presented at the Conference on Retroviruses and Opportunistic Infections (CROI) 2023 in Seattle.
Feb 17, 2023 09:00 am ET
Trodelvy® Demonstrates Positive Efficacy Treating Both Platinum-Ineligible and Rapidly Progressing, Post-Platinum Metastatic Urothelial Cancer
Gilead Sciences, Inc. (Nasdaq: GILD) today announced new and updated positive results from three cohorts of the Phase 2 TROPHY-U-01 study of Trodelvy® (sacituzumab govitecan-hziy) for the treatment of metastatic urothelial cancer (mUC). These data demonstrate that Trodelvy produced both rapid and durable responses for patients across a range of hard-to-treat types of mUC including platinum-ineligible and rapidly progressing, post-platinum mUC. These findings will be featured in both an oral session (abstract #520) and in poster presentations (abstract #518, #526) during the 2023 Ame
Feb 14, 2023 08:45 am ET
Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new clinical and real-world data from the company’s HIV, COVID-19 and viral hepatitis research and development programs at the 30th Conference on Retroviruses and Opportunistic Infections (CROI) from February 19-22. Seventy abstracts, including late-breaking data, demonstrate Gilead’s continued expertise and leadership in virology with a commitment to advance the next wave of scientific discovery to treat, prevent, cure and help eradicate viral diseases.
Feb 09, 2023 07:15 am ET
Kite’s Tecartus® CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Kite, a Gilead Company (Nasdaq: GILD), today announced the three-year follow-up results from the pivotal ZUMA-3 study of the CAR T-cell therapy Tecartus® (brexucabtagene autoleucel). Results from the analysis showed a median overall survival (OS) of 26 months and demonstrated that responses remained durable in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) with a consistent safety profile observed since the two-year analysis. These findings were presented today during a poster session at the 5th European CAR T-cell Meeting, taking place in
Feb 03, 2023 10:29 am ET
U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) has approved Trodelvy® (sacituzumab govitecan-hziy) for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. The approval is based on statistically significant and clinically meaningful progression-free survival an
Feb 02, 2023 04:05 pm ET
Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2023 Dividend
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 2.7% in the company’s quarterly cash dividend, beginning in the first quarter of 2023. The increase will result in a quarterly dividend of $0.75 per share of common stock. The dividend is payable on March 30, 2023, to stockholders of record at the close of business on March 15, 2023. Future dividends will be subject to Board approval.
Feb 02, 2023 04:01 pm ET
Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2022.
Feb 01, 2023 08:35 am ET
Gilead Awards $7.6 Million in Grants to Advance Health Equity in Breast Cancer
Gilead Sciences, Inc. (Nasdaq: GILD) awarded $7.6 million in grant funding to 24 U.S.-based, community organizations through the newly created Toward Health Equity (THE) Oncology Grant™. The funding will support evidence-based interventions that address barriers to care and social determinants of health including patient navigator training, cultural competency training, and services combating barriers such as transportation.
Jan 30, 2023 09:00 am ET
Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic collaboration to co-develop
Jan 27, 2023 04:05 pm ET
Gilead Sciences to Present at Upcoming Investor Conferences
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:
Jan 19, 2023 04:05 pm ET
Gilead Sciences to Release Fourth Quarter & Full Year 2022 Financial Results on Thursday, February 2, 2023
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2022 financial results and full year 2023 financial guidance will be released on Thursday, February 2 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s fourth quarter and full year 2022 financial results and provide a business update.
Jan 05, 2023 01:50 pm ET
Gilead Sciences Again Named to Dow Jones Sustainability World Index
- DJSI World Highlights the Most Sustainable Companies Around the World Based on Corporate Sustainability Assessment -
Jan 04, 2023 10:00 am ET
Gilead Sciences: Connecting Breast Cancer Education to Community: Equal Hope
NORTHAMPTON, MA / ACCESSWIRE / January 4, 2023 / Gilead Sciences
Jan 03, 2023 08:30 am ET
European Medicines Agency Validates Marketing Authorization Application For Trodelvy® (sacituzumab govitecan-hziy) For Pre-treated HR+/HER2- Metastatic Breast Cancer
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Medicines Agency (EMA) has validated a Type II variation Marketing Authorization Application (MAA) for Trodelvy® (sacituzumab govitecan-hziy) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.
Jan 03, 2023 08:30 am ET
Gilead and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies
Gilead Sciences, Inc. (Nasdaq: GILD) and EVOQ Therapeutics, Inc. (EVOQ) today announced a collaboration and licensing agreement to advance EVOQ’s proprietary technology for the treatment of rheumatoid arthritis (RA) and lupus. EVOQ’s NanoDisc technology is designed to enable lymph-targeted delivery of disease-specific antigens and has the p
Dec 27, 2022 04:30 pm ET
Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce Therapeutics
Gilead Sciences, Inc. (Nasdaq: GILD) and Jounce Therapeutics, Inc. (Nasdaq: JNCE) amended their existing license agreement for GS-1811 (formerly JTX-1811), enabling Gilead to buyout remaining contingent payments potentially due under the license...
Dec 27, 2022 04:30 pm ET
Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics
Gilead Sciences, Inc. (Nasdaq: GILD) and Jounce Therapeutics, Inc. (Nasdaq: JNCE) amended their existing license agreement for GS-1811 (formerly JTX-1811), enabling Gilead to buy out remaining contingent payments potentially due under the license agreement executed in August 2020. As part of the transaction, certain operational obligations of the parties related to GS-1811, an anti-CCR8 antibody, set forth in the license agreement have also been terminated. Gilead will acquire certain related intellectual property, including all outstanding rights of Jounce to GS-1811, pursuant to the transact
Dec 23, 2022 04:05 pm ET
Gilead Sciences to Present at Upcoming Investor Conference
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference:
Dec 22, 2022 04:30 pm ET
Yescarta® Now Approved in Japan for Initial Treatment of Relapsed/Refractory Large B-Cell Lymphoma
Kite Pharma, Inc., a Gilead Company, (hereafter, Kite) (NASDAQ: GILD) and Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo) (TSE: 4568) today jointly announced that the Japan Ministry of Health, Labour and Welfare (MHLW) has approved Yescarta (axicabtagene ciloleucel), a chimeric antigen receptor (CAR) T-cell therapy, for the initial treatment of patients with relapsed/refractory large B-cell lymphoma ( R/R LBCL): diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, transformed follicular lymphoma, and high-grade B-cell lymphoma. Yescarta should be used only in patients
Dec 22, 2022 10:27 am ET
Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Sunlenca® (lenacapavir), in combination with other antiretroviral(s) (ARV), has been granted approval by the U.S. Food and Drug Administration (FDA) for the treatment of HIV-1 infection in heavily treatment-experienced (HTE) adults with multi-drug resistant (MDR) HIV-1 infection. Sunlenca has a multi-stage mechanism of action distinguishable from other currently approved classes of antiviral agents and no known cross resistance exhibited in vitro to other existing drug classes. Sunlenca offers a new, twice-yearly treat
Dec 21, 2022 09:30 am ET
Gilead Sciences: Tatiana Williams Leads the Way With the Transinclusive Group
NORTHAMPTON, MA / ACCESSWIRE / December 21, 2022 / When Tatiana Williams was growing up as a young Trans woman in Florida, she faced many challenges and hardships - but she didn't find many resources available to her.
Dec 20, 2022 08:00 am ET
Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer
Kite, a Gilead Company (Nasdaq: GILD), and Tmunity Therapeutics (Tmunity), today announced that the companies have signed an agreement in which Kite will acquire Tmunity, a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies. The acquisition of Tmunity complements Kite’s existing in-house cell therapy research capabilities by adding additional pipeline assets, platform capabilities, and a strategic research and licensing agreement with the University of Pennsylvania (Penn).
Dec 19, 2022 05:00 pm ET
Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced positive results from the fourth interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% without epidermal growth factor receptor or anaplastic lymphoma kinase (EGFR/ALK) mutations. ARC-7 is a Phase 2, multicenter, three-arm, randomized, open-label study evaluating the combinations of Fc-silent anti-TIGIT monoclonal antibody domvanalimab plus anti-PD1 monoclonal antibody zimberelimab (doublet) and domva
Dec 19, 2022 05:00 pm ET
Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced positive results from the fourth interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% without epidermal growth factor receptor or anaplastic lymphoma kinase (EGFR/ALK) mutations. ARC-7 is a Phase 2, multicenter, three-arm, randomized, open-label study evaluating the combinations of Fc-silent anti-TIGIT monoclonal antibody domvanalimab plus anti-PD-1 monoclonal antibody zimberelimab (doublet) and domv
Dec 15, 2022 08:15 am ET
Gilead Sciences: Latinas Contra Cancer Empowers Patients To Advocate for Change
NORTHAMPTON, MA / ACCESSWIRE / December 15, 2022 / When Darcie Green's dad got sick, she thought she was prepared to help him navigate the healthcare system. She'd spent her entire career in healthcare policy. But as he got sicker and his care got more complicated, she found herself in over her head.
Dec 12, 2022 11:00 am ET
Gilead Sciences Again Named to Dow Jones Sustainability World Index
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company has once again been recognized as one of the most sustainable pharmaceutical companies according to the Dow Jones Sustainability World Index (DJSI World). This ranking is based on an in-depth analysis of Gilead’s sustainability performance and highlights the company’s longstanding sustainable business practices and transparency on environmental, social and governance (ESG) issues.
Dec 12, 2022 10:00 am ET
New Analyses of Kite's Tecartus® CAR T-Cell Therapy Provide Additional Evidence Supporting Overall Survival and Durability of Response
Kite, a Gilead Company (Nasdaq: GILD), today announced findings from follow-up analyses of two pivotal studies (ZUMA-2 and ZUMA-3) of the CAR T-cell therapy Tecartus® (brexucabtagene autoleucel). A comparison of two-year follow-up from ZUMA-3 and SCHOLAR-3, a retrospective historical control study, evaluating Tecartus versus standard of care (SOC) in adult patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), was presented in a poster session at the 2022 American Society of Hematology (ASH) Annual Meeting & Exposition on December 10 (Abstract #1368) an
Dec 12, 2022 10:00 am ET
Three-Year Follow-Up Analysis of Kite’s Yescarta® CAR T-cell Therapy (ZUMA-5 Trial) - 52% of Patients With Indolent Lymphomas Continued to Have Ongoing Responses at a Median Follow-Up of 40.5 Months
Kite, a Gilead Company (Nasdaq: GILD), today announced three-year follow-up data from the pivotal ZUMA-5 study for Yescarta® (axicabtagene ciloleucel) in relapsed or refractory (r/r) indolent non-Hodgkin lymphoma (iNHL), showing continued response in 52% of all enrolled patients, and prolonged duration of progression-free survival (PFS) in the Phase 2 study, presented at the 2022 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract #4660). In addition, two-year follow-up data from the ZUMA-1 safety cohort (Cohort 6) evaluating use of prophylactic corticosteroid
Dec 11, 2022 05:30 pm ET
Body of Evidence Grows From ZUMA-7 Study Supporting Initial Treatment With Kite’s Yescarta® CAR T-cell Therapy for Patients With Relapsed or Refractory Large B-cell Lymphoma
Kite, a Gilead Company (Nasdaq: GILD), today announced findings from two new analyses of the landmark ZUMA-7 trial of Yescarta® (axicabtagene ciloleucel), the largest and longest follow-up of a CAR T-cell therapy versus standard of care (SOC) in patients with relapsed or refractory large B-cell lymphoma (r/r LBCL). These results include an analysis of outcomes for patients who received subsequent treatment for their lymphoma following second-line Yescarta therapy or SOC therapy, as well as an exploratory analysis of the association between metabolic tumor volume (MTV) and clinical o
Dec 11, 2022 10:00 am ET
Time to CAR T-cell Therapy May Impact Outcomes for Patients With Relapsed/Refractory Large B-cell Lymphoma in New CIBMTR Analysis
Kite, a Gilead Company (Nasdaq: GILD), today announced results from one of the largest real-world analyses of patients who received CAR T-cell therapy assessing the impact of time from leukapheresis to infusion ("vein-to-vein" time) for Yescarta® (axicabtagene ciloleucel) in adult patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL). The analysis reported shorter vein-to-vein times associated with improved outcomes in patients treated with Yescarta, adjusted for key prognostic factors. Data were presented on December 11, during the 2022 American Society of Hematol
Dec 09, 2022 08:17 am ET
Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced a global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe, and broadly accessible therapies.
Dec 09, 2022 07:15 am ET
Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma
-- Collaboration leverages expertise across both companies, including Kite's global cell therapy leadership and industry leading reliable manufacturing --
Dec 08, 2022 09:40 am ET
Gilead Sciences: U.S. Military Veteran Battles Lymphoma With Car T-Cell Therapy: Marcus' Story
NORTHAMPTON, MA / ACCESSWIRE / December 8, 2022 / Marcus arrived home to Mississippi from his military assignment overseas, excited to see his 20-month-old son, when he realized something was wrong.
Dec 07, 2022 04:30 pm ET
Kite and Daiichi Sankyo Announce Changes to YESCARTA® CAR T-Cell Therapy Licensing Agreement in Japan
Kite Pharma, Inc., a Gilead Company, (hereafter Kite) and Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo) today jointly announced the revision of their 2017 partnership agreement, which gave Daiichi Sankyo exclusive rights to develop, manufacture and commercialize Yescarta (axicabtagene ciloleucel) in Japan. Kite was acquired by Gilead Sciences, Inc. later in 2017 after the Daiichi Sankyo partnership agreement. Daiichi Sankyo and Kite have now agreed that the Marketing Authorization for Yescarta will be transferred to Gilead Sciences K.K., the Japan subsidiary of Gilead Sciences, Inc., in
Dec 06, 2022 03:00 pm ET
New Data for Trodelvy Demonstrate Clinical Efficacy Across Trop-2 Expression Levels in HR+/HER2- Metastatic Breast Cancer
Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from a post-hoc analysis from the Phase 3 TROPiCS-02 study evaluating Trodelvy® (sacituzumab govitecan-hziy; SG) versus comparator chemotherapy (physicians’ choice of chemotherapy, TPC) in patients with HR+/HER2- metastatic breast cancer who progressed on endocrine-based therapies and at least two chemotherapies. In the analysis, Trodelvy improved progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) compared with TPC across Trop-2 expression levels. Details of the late-breaking abstract
Nov 29, 2022 08:30 am ET
European Commission Grants Expanded Marketing Authorization for Gilead’s Biktarvy® for the Treatment of HIV in Pediatric Populations
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has authorized a new low-dose tablet dosage form of Biktarvy® (bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg tablets) and an extension of the indication for Biktarvy to treat HIV infection in virologically suppressed children who are at least two years of age and weigh at least 14 kg. The European Marketing Authorization is the first pediatric approval for Biktarvy in the European Union (EU) and applies to all 27 member states of the EU, as well as Norway, Iceland and Liechten
Nov 28, 2022 08:30 am ET
Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-Small Cell Lung Cancer
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences (NYSE: RCUS) today announced a positive update from the fourth interim analysis of the randomized, open-label Phase 2 ARC-7 study in patients with first-line metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% without epidermal growth factor receptor or anaplastic lymphoma kinase (EGFR/ALK) mutations. ARC-7 is evaluating the combinations of anti-TIGIT antibody domvanalimab plus anti-PD-1 antibody zimberelimab (doublet), and domvanalimab plus zimberelimab and etrumadenant, an A2a/b adenosine recept
Nov 28, 2022 08:30 am ET
Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-small Cell Lung Cancer
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences (NYSE: RCUS) today announced a positive update from the fourth interim analysis of the randomized, open-label Phase 2 ARC-7 study in patients with first-line metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% without epidermal growth factor receptor or anaplastic lymphoma kinase (EGFR/ALK) mutations. ARC-7 is evaluating the combinations of anti-TIGIT antibody domvanalimab plus anti-PD-1 antibody zimberelimab (doublet), and domvanalimab plus zimberelimab and etrumadenant, an A2a/b adenosine recept
Nov 15, 2022 04:05 pm ET
Gilead Sciences to Present at Upcoming Investor Conferences
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:
Nov 10, 2022 10:05 am ET
Gilead Sciences: A Career Rooted in Championing Diversity and Inclusion: Jesse's Story
NORHAMPTON, MA / ACCESSWIRE / November 10, 2022 / Gilead Sciences
Nov 03, 2022 09:15 am ET
Gilead and Kite Oncology Demonstrate Transformative Impact of Cell Therapy and Promise of Blood Cancer Portfolio at ASH 2022
Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will support 30 data presentations, including seven oral presentations in large B-cell lymphoma (LBCL), and two oral presentations on investigator-sponsored studies in acute myeloid leukemia (AML) during the 64th Annual American Society of Hematology (ASH) Annual Meeting (December 10-13).
Nov 02, 2022 08:55 am ET
Gilead's Path to Equitable Global COVID-19 Treatment Access
NORTHAMPTON, MA / ACCESSWIRE / November 2, 2022 / Gilead Sciences
Nov 02, 2022 08:00 am ET
Jounce Therapeutics earns clinical milestone payment under the CCR8 exclusive license agreement with Gilead Sciences, Inc.
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced today earning a $15.0 million clinical milestone payment from Gilead...
Nov 02, 2022 07:01 am ET
U.S. Food and Drug Administration Approves Vemlidy® (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Vemlidy® (tenofovir alafenamide) 25 mg tablets as a once-daily treatment for chronic hepatitis B virus (HBV) infection in pediatric patients 12 years of age and older with compensated liver disease.
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.